IGI Email Format
Biotechnology ResearchNew York, United States201-500 Employees
IGI is a global, fully integrated clinical-stage biotechnology company focused on developing biologics for oncology. Based in New York, it maintains a pipeline of novel multispecific antibody candidates aimed at addressing complex diseases and treating patients holistically, supported by its BEAT technology platform. The company concentrates its efforts on hematological malignancies and solid tumors. With a mid-sized footprint, the organization employs several hundred people. In June 2026, IGI announced the appointment of Mariana Cota Stirner, M.D., Ph.D., as Chief Medical Officer, a leadership addition intended to support its clinical programs.